Search Result

Results for "

migraine headache

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (14) Apoptosis (6) Autophagy (13) Biochemical Assay Reagents (1) CGRP Receptor (1) Drug Derivative (1) Drug Intermediate (1) Endogenous Metabolite (14) HDAC (13) Histamine Receptor (1) HIV (13) Isotope-Labeled Compounds (8) Mitophagy (13) NADPH Oxidase (1) NO Synthase (1) Notch (13) Organoid (5) Prostaglandin Receptor (2) Reference Standards (3) TRP Channel (1)
By Research Areas:	Cancer (13) Cardiovascular Disease (1) Infection (6) Inflammation/Immunology (1) Metabolic Disease (5) Neurological Disease (28)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10585

Valproic acid 60+ Cited Publications VPA; 2-Propylpentanoic acid; Dipropylacetic acid	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585A

Valproic acid sodium 60+ Cited Publications Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-B0121B

Sumatriptan 5+ Cited Publications GR 43175 free base	5-HT Receptor	Neurological Disease
Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC₅₀s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT_1D, 5-HT_1B and 5-HT_1F receptors, respectively. Sumatriptan can be used for migraine headache research .

HY-P99021

Galcanezumab 1 Publications Verification LY 2951742	CGRP Receptor	Neurological Disease
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .

HY-B0121

Sumatriptan succinate 5+ Cited Publications GR 43175 succinate	5-HT Receptor	Neurological Disease
Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with IC₅₀s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT_1D, 5-HT_1B and 5-HT_1F receptors, respectively. Sumatriptan succinate can be used for migraine headache research .

HY-10585S

Valproic acid-d4 1 Publications Verification VPA-d₄; 2-Propylpentanoic acid-d₄	HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S1

Valproic acid-d6 VPA-d₆; 2-Propylpentanoic acid-d₆	HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-78509

Dibenzosuberone	Biochemical Assay Reagents Drug Intermediate	Neurological Disease
Dibenzosuberone belongs to the family of tricyclic antidepressant drugs, commonly referred to as Tricyclic antidepressants (TCAs), and is widely used in research on migraine, tension headaches, anxiety disorders, and schizophrenia. Dibenzosuberone is also a key intermediate in the synthesis of various active pharmaceutical ingredients (APIs), such as Amitriptyline (HY-B0527), Nortriptyline (HY-118620), Noxiptiline or Cyproheptadine (HY-B1622) .

HY-10585S2

Valproic acid-d15 VPA-d₁₅; 2-Propylpentanoic acid-d₁₅	HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585B

Valproic acid sodium (2:1) Sodium Valproate (2:1); VPA sodium (2:1); 2-Propylpentanoic acid sodium (2:1)	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585AR

Valproic acid sodium (Standard) Sodium Valproate (Standard); VPA sodium (Standard); 2-Propylpentanoic acid sodium (Standard)	Organoid Reference Standards HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585S4

Valproic acid-d4-1 VPA-d₄-1; 2-Propylpentanoic acid-d₄-1	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-130579

Vinyl-L-NIO hydrochloride L-VNIO hydrochloride	NO Synthase NADPH Oxidase	Cardiovascular Disease Neurological Disease
Vinyl-L-NIO (L-VNIO) hydrochloride is a neuronal nitric oxide synthase (NOS) inhibitor with a rat K_i of 0.10 μM. Vinyl-L-NIO hydrochloride inhibits NADPH oxidase activity, attenuates renal fibrosis, inflammation, oxidative stress indices, and albuminuria. Vinyl-L-NIO hydrochloride can be used for the research of parkinson's disease, migraine headache, and hypertension .

HY-123442

L 775,606	5-HT Receptor	Neurological Disease
L 775,606 is a potent and selective 5-HT1D receptor agonist. L 775,606 can be used to study migraine headache .

HY-B0121R

Sumatriptan succinate (Standard) GR 43175 succinate (Standard)	5-HT Receptor Reference Standards	Neurological Disease
Sumatriptan (succinate) (Standard) is the analytical standard of Sumatriptan (succinate). This product is intended for research and analytical applications. Sumatriptan succinate (GR 43175) is an orally active 5-HT1 receptor agonist with K_is of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research .

HY-B0121BR

Sumatriptan (Standard) GR 43175 free base (Standard)	5-HT Receptor Reference Standards	Neurological Disease
Sumatriptan (Standard) is the analytical standard of Sumatriptan. This product is intended for research and analytical applications. Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC50s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively. Sumatriptan can be used for migraine headache research .

HY-10585AG

Valproic acid sodium Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-W794759

Valproic acid magnesium Magnesium valproate; VPA magnesium; 2-Propylpentanoic acid magnesium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Cancer
Valproic acid magnesium (Magnesium valproate) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM. Valproic acid magnesium inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid magnesium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid magnesium is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-106736

Etilefrine pivalate hydrochloride	Drug Derivative	Neurological Disease
Etilefrine pivalate hydrochloride is an orally active compound and can be used for study of migraine headaches .

HY-119121

JNJ-38893777	TRP Channel	Neurological Disease
JNJ-38893777 is an orally active and highly selective transient receptor potential vanilloid type 1 (TRPV1) channel antagonist. JNJ-38893777 inhibits neuronal hyperactivation and reduces inflammatory hyperalgesia. JNJ-38893777 is promising for research of migraine headaches, neuropathic and inflammatory pain .

HY-B1658

Frovatriptan (R)-Frovatriptan; SB 209509; VML 251	5-HT Receptor	Neurological Disease
Frovatriptan is a potent 5-HT_1B//D receptor agonist and has the highest 5-HT_1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura .

HY-110351

BGC-20-1531 hydrochloride PGN 1531 hydrochloride	Prostaglandin Receptor	Neurological Disease
BGC 20-1531 (PGN 1531) hydrochloride is a potent and selective prostanoid EP₄ receptor antagonist, with a pK_b of 7.6. BGC 20-1531 hydrochloride has the potential for the research of migraine headache .

HY-10585AS1

Valproic acid-d14 sodium Sodium Valproate-d14; VPA-d14 sodium; 2-Propylpentanoic acid-d14 sodium	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585AS

Valproic acid-d7 sodium Sodium Valproate-d7; VPA-d7 sodium; 2-Propylpentanoic acid-d7 sodium	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S3

Valproic acid-d4 sodium Sodium Valproate-d4; VPA-d4 sodium; 2-Propylpentanoic acid-d4 sodium	Isotope-Labeled Compounds HDAC Autophagy Mitophagy HIV Notch Endogenous Metabolite	Cancer
Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-19849

BGC-20-1531 free base PGN 1531 free base	Prostaglandin Receptor	Neurological Disease
BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP₄ receptor antagonist, with a pK_B of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache .

HY-W018475

Rizatriptan MK 462 free base	5-HT Receptor	Neurological Disease
Rizatriptan (MK 462 free base) is an orally active 5-HT_1B/5-HT_1D receptor agonist, with BBB permeability. Rizatriptan exerts significant anti-migraine effects by constricting intracranial and extracranial blood vessels and inhibiting neuropeptide release. Rizatriptan exhibits species- and tissue-specific metabolic characteristics; for example, it undergoes oxidative deamination mainly by MAO-A in the liver of brown rats, so co-administration with MAO-A inhibitors is prohibited. Rizatriptan may also exacerbate nitroglycerin-induced cutaneous allodynia, prolong the duration of central sensitization, and increase anxiety-like behavior and active drug-seeking behavior in mice. Rizatriptan has been widely used in studies related to migraine and medication-overuse headache .

HY-B0121A

Sumatriptan hydrochloride GR 43175 hydrochloride	5-HT Receptor	Neurological Disease
Sumatriptan hydrochloride (GR 43175) is an orally active 5-HT1 receptor agonist with IC₅₀s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT_1D, 5-HT_1B and 5-HT_1F receptors, respectively. Sumatriptan hydrochloride can be used for migraine headache research .

HY-B0121BS2

Sumatriptan-d5 GR 43175 free base-d5	5-HT Receptor Isotope-Labeled Compounds	Neurological Disease
Sumatriptan-d₅ is deuterated labeled Sumatriptan (HY-B0121B). Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC₅₀s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT_1D, 5-HT_1B and 5-HT_1F receptors, respectively. Sumatriptan can be used for migraine headache research .

HY-101635

Proxibarbal Proxibarbital	5-HT Receptor Histamine Receptor	Neurological Disease
Proxibarbal is a barbiturate derivative. Proxibarbal has anti-anxiety properties and is also used for the study of migraine headaches.

HY-P2428

RI-61	Endogenous Metabolite	Neurological Disease
RI-61 is a compound that has activity in suppressing migraine, cluster headache, new daily persistent headache and cyclical vomiting syndrome. RI-61 has shown significant efficacy in relieving the symptoms of these disorders. RI-61 helps relieve pain and other related symptoms by modulating the action of neurotransmitters .

HY-B1658S

Frovatriptan-d3 hydrochloride (R)-Frovatriptan-d3 hydrochloride; SB 209509-d3 hydrochloride; VML 251-d3 hydrochloride	5-HT Receptor	Neurological Disease
Frovatriptan-d₃ (hydrochloride) is the deuterium labeled Frovatriptan . Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura .

HY-B0121BS1

Sumatriptan-d6 GR 43175 free base-d₆	Isotope-Labeled Compounds 5-HT Receptor	Neurological Disease
Sumatriptan-d₆ is the deuterium labeled Sumatriptan. Sumatriptan is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan can be used for migraine headache research .

HY-B0121BS

Sumatriptan-d6 succinate 1 Publications Verification GR 43175C-d₆	5-HT Receptor Isotope-Labeled Compounds	Neurological Disease
Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active 5-HT1 receptor agonist with K_is of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research .

HY-B0121BS3

Sumatriptan-d6 formate GR 43175 free base-d6 formate	Isotope-Labeled Compounds 5-HT Receptor	Neurological Disease
Sumatriptan-d₆ (formate) (GR 43175 free base-d₆ (formate)) is deuterium labeled Sumatriptan. Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC₅₀s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT_1D, 5-HT_1B and 5-HT_1F receptors, respectively. Sumatriptan can be used for migraine headache research .

Cat. No.	Product Name	Type

HY-10585AG

Valproic acid sodium Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Fluorescent Dyes
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Valproic acid sodium

Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium

Fluorescent Dyes

Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Cat. No.	Product Name	Type

HY-10585AG

Valproic acid sodium Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Biochemical Assay Reagents
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Valproic acid sodium

Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P2428

RI-61	Endogenous Metabolite	Neurological Disease
RI-61 is a compound that has activity in suppressing migraine, cluster headache, new daily persistent headache and cyclical vomiting syndrome. RI-61 has shown significant efficacy in relieving the symptoms of these disorders. RI-61 helps relieve pain and other related symptoms by modulating the action of neurotransmitters .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99021

Galcanezumab 1 Publications Verification LY 2951742	CGRP Receptor	Neurological Disease
Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10585

Valproic acid 60+ Cited Publications VPA; 2-Propylpentanoic acid; Dipropylacetic acid	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585A

Valproic acid sodium 60+ Cited Publications Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Infection Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585B

Valproic acid sodium (2:1) Sodium Valproate (2:1); VPA sodium (2:1); 2-Propylpentanoic acid sodium (2:1)	Infection Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

HY-10585AR

Valproic acid sodium (Standard) Sodium Valproate (Standard); VPA sodium (Standard); 2-Propylpentanoic acid sodium (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Organoid Reference Standards HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Cat. No.	Product Name	Chemical Structure

HY-10585S

Valproic acid-d4

1 Publications Verification

Valproic acid-d₄ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S1

Valproic acid-d6

Valproic acid-d₆ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S2

Valproic acid-d15

Valproic acid-d₁₅ is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S4

Valproic acid-d4-1

Valproic acid-d₄-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585AS1

Valproic acid-d14 sodium

Valproic acid-d₁₄ (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-10585AS

Valproic acid-d7 sodium

Valproic acid-d₇ (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches .

HY-10585S3

Valproic acid-d4 sodium

Valproic acid-d₄ (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.

HY-B0121BS2

Sumatriptan-d5
Sumatriptan-d₅ is deuterated labeled Sumatriptan (HY-B0121B). Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC₅₀s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT_1D, 5-HT_1B and 5-HT_1F receptors, respectively. Sumatriptan can be used for migraine headache research .

HY-B1658S

Frovatriptan-d3 hydrochloride
Frovatriptan-d₃ (hydrochloride) is the deuterium labeled Frovatriptan . Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura .

HY-B0121BS1

Sumatriptan-d6
Sumatriptan-d₆ is the deuterium labeled Sumatriptan. Sumatriptan is an orally active 5-HT1 receptor agonist with Kis of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan can be used for migraine headache research .

HY-B0121BS

Sumatriptan-d6 succinate 1 Publications Verification
Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active 5-HT1 receptor agonist with K_is of 17 nM, 27 nM and 100 nM for 5-HT1D, 5-HT1B and 5-HT1A receptors, respectively. Sumatriptan succinate can be used for migraine headache research .

HY-B0121BS3

Sumatriptan-d6 formate
Sumatriptan-d₆ (formate) (GR 43175 free base-d₆ (formate)) is deuterium labeled Sumatriptan. Sumatriptan (GR 43175) is an orally active 5-HT1 receptor agonist with IC₅₀s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT_1D, 5-HT_1B and 5-HT_1F receptors, respectively. Sumatriptan can be used for migraine headache research .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10585AG

Valproic acid sodium Sodium Valproate; VPA sodium; 2-Propylpentanoic acid sodium	Organoid HDAC Autophagy Mitophagy HIV Notch Apoptosis Endogenous Metabolite	Infection Neurological Disease Metabolic Disease Cancer
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC₅₀ in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC₅₀, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

migraine headache

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products